Overview
- By mid‑July the Democratic Republic of the Congo has reported roughly 1,900–2,011 confirmed Ebola cases and more than 700 deaths while WHO models estimate the real total could be two to four times larger.
- The epidemic is driven by the Bundibugyo variant for which there is no approved vaccine or standard treatment, and the WHO‑sponsored PARTNERS trial began in early July testing remdesivir and the experimental antibody MBP134 with results expected to take months.
- Response capacity has expanded with more treatment beds and labs but is strained by a funding shortfall—WHO requested $115 million and has received about 40%—and by workforce disruptions including a strike by unpaid staff at a treatment centre in Ituri.
- Surveillance gaps are severe: about 80% of new cases are not on contact lists and many recent deaths occurred in the community before patients reached care, which prevents rapid isolation, contact tracing and safe burials.
- The virus has spread beyond Ituri to several eastern provinces and to Uganda, so officials say priority actions are restoring timely pay for health workers, strengthening testing and tracing, and rebuilding community trust to stop further spread.